Amedisys Welcomes Adam Holton as Chief People Officer

BATON ROUGE, La., Sept. 27, 2022 (GLOBE NEWSWIRE) — Amedisys, Inc. (NASDAQ:AMED), a leading home health, hospice, personal care and high-acuity care company, announced today that Adam Holton will join the Company as Chief People Officer.

With more than 20 years of experience, Holton is an expert in leading people strategies that drive exceptional business outcomes including talent acquisition, total rewards, organizational and leadership development, employee engagement, talent management and metrics and analytics.

Most recently, Holton was the Chief Human Resources Officer at Numotion, an organization dedicated to improving the lives of people with disabilities. He previously served in the same role at CHS, Inc, a F100 diversified global agribusiness cooperative that creates connections to empower agriculture. Holton has also held several HR leadership positions with General Electric, USAA and Bank One.

Holton served for eight years in the United States Marine Corps as an Infantry Officer, stationed at Camp Pendleton, California and Quantico, Virginia. In 2004, he deployed with a Marine Corps reserve Infantry Battalion as a Company Commander to Lutafiyah, Iraq, as a part of Operation Iraqi Freedom.

“At Amedisys, we strive to create an exceptional employee experience because our people are the heart of what we do,” stated President and Chief Executive Officer Chris Gerard. “In an increasingly competitive talent market, the attraction and retention of high performing diverse talent is key, and Adam’s depth of expertise will help us achieve this strategy so we can continue to deliver the highest quality of care to our patients and their families.”

“People are the most valued and essential part of any organization. I am passionate about being a part of a caregiving culture that attracts, supports and develops people to their fullest and helping Amedisys achieve its vision,” stated Chief People Officer Adam Holton. “I’m honored and excited to join this exceptional company and look forward to contributing to its important mission of allowing patients to receive the care they need where they most want to be, in the home.”

About Amedisys:

Amedisys, Inc. is a leading healthcare at home Company delivering personalized home health, hospice, personal care and high-acuity care services. Amedisys is focused on delivering the care that is best for our patients, whether that is home-based personal care; inpatient hospital, palliative, and skilled nursing facility (“SNF”) care in their homes; recovery and rehabilitation after an operation or injury; care focused on empowering them to manage a chronic disease; or hospice care at the end of life. More than 3,000 hospitals and 90,000 physicians nationwide have chosen Amedisys as a partner in post-acute care. Founded in 1982, headquartered in Baton Rouge, LA with an executive office in Nashville, TN, Amedisys is a publicly held company. With approximately 21,000 employees, in 550 care centers in 38 states and the District of Columbia, Amedisys is dedicated to delivering the highest quality of care to the doorsteps of more than 445,000 patients in need every year, performing more than 11.5 million visits annually. For more information about the Company, please visit: www.amedisys.com

Contact:

Kendra Kimmons
Vice President of Marketing & Communications
225-299-3708
kendra.kimmons@amedisys.com

Staff

Recent Posts

Vivos Inc.’s IsoPet® Division Achieves Exceptional Growth in 2024, Expanding Certified Veterinary Clinics Nationwide

Richland, WA, Dec. 26, 2024 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL) is pleased to…

2 hours ago

Assembly Biosciences Reports Interim Phase 1b Results from Clinical Trial Evaluating Next-Generation Capsid Assembly Modulator Candidate ABI-4334 in Chronic Hepatitis B

– ABI-4334 was well-tolerated with a favorable safety profile and half-life supporting once-daily oral dosing…

2 hours ago

Optinose Announces 1-for-15 Reverse Stock Split

YARDLEY, Pa., Dec. 26, 2024 (GLOBE NEWSWIRE) -- Optinose, Inc. (NASDAQ: OPTN), a pharmaceutical company…

2 hours ago

TScan Therapeutics Announces $30 Million Registered Direct Offering at a 37% Premium

WALTHAM, Mass., Dec. 26, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage…

2 hours ago

Clearmind Medicine Looks to Move Forward with its Novel Psychedelic MEAI- Based Alcohol Substitute

Company recently signed a non-binding term sheet with Dr Glitter Pty Ltd for mutual development…

2 hours ago

SciSparc: AutoMax Announces $13 Million First Delivery of JAC Vehicles Following Regulatory Approval for Direct Importation

TEL AVIV, Israel, Dec. 26, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or…

2 hours ago